AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01236716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel plus carboplatin
Description: Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
Study NCT03541356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 140 mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device with four puffs, two to each nostril
Study NCT03541356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: L-dopa 70mg/carbidopa 7mg
Description: Delivered via the I231 POD (Precision Olfactory Delivery) device with two puffs, one to each nostril
Study NCT02030509 — intervention group
Intervention type: OTHER
Intervention: Quick diagnosis program
Study NCT04683874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed tray
Description: 3D printed tray
Study NCT02972086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Description: A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
Study NCT03299439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: a stimulation of the body or auricular points
Study NCT03299439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: a stimulation of the body or auricular points
Study NCT02353572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT02353572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT02353572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT02353572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Transplant
Description: Undergo autologous hematopoietic stem cell transplant
Study NCT01118949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
Study NCT01102608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
Study NCT03449420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: thromboelastography
Description: TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
Study NCT03501017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics.
Study NCT03501017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Practice
Description: As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
Study NCT01395342 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Exercise using stationary bicycle
Description: Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position.
Study NCT04596618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm cooling
Description: forearm cooling will be performed for active cooling assessment.
Study NCT00803582 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Description: Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
Study NCT00803582 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Placebo acupuncture
Description: Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
Study NCT01450670 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Kibow Biotics
Description: Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
Study NCT04551612 — intervention group
Intervention type: RADIATION
Intervention: Multislice computed tomography temporal bone
Description: Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient
Study NCT04301401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal swabs
Description: On the day of the surgical intervention, vaginal swabs will be taken at various stages of surgery: before vaginal disinfection/draping, directly after disinfection/draping, 1 hour after disinfection, 6 weeks after surgery and 12 months after surgery.
Study NCT04301401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool samples
Description: Stool samples will also be taken (and collected in a pot devoted to coproculture with an airtight opaque bag given to the patient) at the inclusion visit on the day before surgery and also 6 weeks after surgery (in a second pot with an airtight opaque bag given to the patient at the time of being discharged).
Study NCT04301401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine samples
Description: Urine samples will also be taken before surgery and 6 weeks after surgery.
Study NCT03479619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device A
Description: Glucoject Dual Plus lancing device
Study NCT02219815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehab Intervention
Description: Pre-operative, structured exercise intervention.
Study NCT03479619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device B
Description: Droplet lancing device
Study NCT03479619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lancing device C
Description: Commercially available lancing device
Study NCT03479619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 28 G lancet
Description: Droplet 28 G
Study NCT03479619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 G lancet
Description: Droplet personal lancet 30 G
Study NCT03064646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organ Preservation
Description: Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
Study NCT02564133 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: A transthoracic echocardiography is performed to discover a patent foramen ovale
Study NCT00834665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT vaccine, GM-CSF, PCV, T cell infusion
Description: hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
Study NCT00834665 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF, PCV, T cell infusion
Description: Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
Study NCT02148523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison to peers
Study NCT02148523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence feedback
Study NCT02148523 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Study NCT02148523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic pill bottle
Description: This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
Study NCT04341714 — intervention group
Intervention type: OTHER
Intervention: Satisfaction evaluation
Description: Assessement of satisfaction of the telephone consultation
Study NCT03059381 — intervention group
Intervention type: DRUG
Intervention: Fycompa
Description: The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
Study NCT04147338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.
Study NCT01457872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength-based case management
Description: Strength-based case management
Study NCT01457872 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control condition - referral only
Description: Referral only
Study NCT05549193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises Training
Description: Pelvic Floor Muscle Training: For slow contractions, it was asked to contract in 5 seconds gradually, wait at a maximum of 5 seconds and gradually relax in 5 seconds. For fast contractions, it was asked to contract at a maximum of 2 seconds and then to relax. 10 fast + 10 slow contractions were accepted as 1 set exercise. (10 sets x Every Day x 6 weeks)~Transversus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically. 15 repetitions were carried out, each consisting of contraction for 10 s and relaxation for 20 s. 2 sets of 15 repetitions were done.~Internal Obliquus Abdominus: Patients were in the crook lying position and were asked to contract their abdominal muscles strongly and statically and then try to touch the furthest point of their legs with their fingertips for 15 repetitions consisting of contraction for 10 s followed by relaxation for 20 s. The sequence was then repeated on the other leg.
Study NCT02398552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
Study NCT02398552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
Study NCT02787252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant procedure, Freedom Spinal Cord Stimulation System
Description: A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
Study NCT04266808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: An interactive telehealth monitoring and biofeedback system
Description: A pressure sensitive mat located under the user's wheelchair seat cushion and a wheelchair propulsion monitoring device attached to the chair which are interfaced with a phone App based user interface to provide feed back to promote physical activity and pressure relief maneuver performance among wheelchair users.
Study NCT02285231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginyl-fructose
Study NCT02285231 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03479619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 33 G lancet
Description: Droplet personal lancet 33 G
Study NCT01529853 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for SAR156597)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study NCT00538629 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT01107717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin\pioglitazone\exenatide
Description: metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
Study NCT00222469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10mg/kg IV on Day 1 Q 2 weeks
Study NCT00222469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
Study NCT00222469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 100mg/m2 on Day 2 and Q 2 weeks.
Study NCT03436368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous spinal anesthesia
Description: Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
Study NCT03436368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
Study NCT04334642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mindfulness based intervention
Description: It is a pilot study of feasibility and preliminary effectiveness composed of a longitudinal intervention that uses as a baseline measure a Mindfulness Training of 2 cycles (each cycle is formed by 4 days of intervention); two follow-up measures (1 and 6 months after the 2nd cycle); and a final measurement (12 months after the start of the study).
Study NCT04223076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%, Corsodyl
Description: Comparison of Corsodyl and Curasept
Study NCT04223076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.2%, Curasept
Description: Chlorhexidine 0.2% mouthwash with an Anti Discoloring System (ADS)
Study NCT01929668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Study NCT01107717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, glyburide and glargine
Description: subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c \< 6.5%
Study NCT03479619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (1)
Description: The lowest depth setting (1)
Study NCT03479619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lancing depth setting (5)
Description: The highest depth setting (5)
Study NCT01118429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Description: Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Study NCT04034875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: questionnaire
Study NCT01696266 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
Study NCT04642040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Positioning,breathing techniques (diaphragmatic breathing, alternate breathing, and pursed-lip breathing),respiratory muscle exercises, joint ROM exercises, early-mobilization and progressive ambulation, peripheral muscle strengthening exercises
Study NCT02427425 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Study NCT02427425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Study NCT01118429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Study NCT01237704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rehabilitation (TR)
Description: TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
Study NCT01237704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical stimulation (ES)
Description: Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
Study NCT03644927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive exercise training
Description: The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
Study NCT03644927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing.
Study NCT01503502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flumatinib
Description: Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
Study NCT01503502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib
Description: Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
Study NCT03296397 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Gardasil
Description: Vaccination with Gardasil in patients apparently cured of external genital warts